Algernon Pharmaceuticals (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau shared news with Steve Darling from Proactive that the company will be sharing interim data from its multi-national Ifenprodil Phase 2b/3 COVID-19 human study.
Moreau telling Proactive this data will consist of 75 patients on day 15 of the study and will be presented in a descriptive statistics format and the Company is projecting the data readout will be in the first week of December 2020.
Price: 0.235 CAD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Algernon Pharmaceuticals Inc. named herein, including the promotion by the Company of Algernon Pharmaceuticals Inc. in any Content on the Site,...
FOR OUR FULL DISCLAIMER CLICK HERE
Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive with news the company has received interim data from the Phase 2b part of their Phase 2b/3 clinical study of Ifenprodil for COVID-19. Moreau telling Proactive what the data showed...
Retail & consumer
Prev article
